Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Psychiatry is in need of tools to improve personalized treatment given the high rates of adverse drug reactions and generally low remission rates. Here, I discuss how pharmaco-genetics approaches have elucidated that some treatment outcomes in severe psychiatric disorders are associated with polygenic risk profiles. I also give examples of real-world epidemiological approaches that have potential to curtail risks ofpsychotropic mediation use and improve response rates. Finally, I summarize some of the insights Mendelian Randomization studies conducted at my lab have provided. Overall, the aim of the talk is to critically appraise the hypothesis that more personalized prescribing is possible in psychiatry. I look forward to critical thoughts, suggestions, lively discussions, and possible future collaborations.

 

Hosted in the Seminar Room, to attend via Zoom, please use the joining details below: